Change Request |
Reference: | Change Request 257 |
Version No: | 1.7 |
Subject: | DSCN 23/2002 |
Type of Change: | Revision of NHS data standards |
Effective Date: | 1 June 2002 |
Reason for Change: | Integration of the Chemotherapy HRGs required to support casemix adjusted costs into the NHS Data Dictionary & Manual |
The mandatory collection of Chemotherapy HRGs came into force on 1st October 2001 and the following are changes to the NHS Data Dictionary & Manual to reflect this collection. The changes in this paper have been developed to align with the National Cancer Data Set Project set of data items that have been proposed for integration into NHS data standards.
Summary of changes:Class Definitions | |
ANTI-CANCER DRUG CYCLE | New Class |
ANTI-CANCER DRUG FRACTION | New Class |
ANTI-CANCER DRUG PROGRAMME | Change to description |
ANTI-CANCER DRUG PROGRAMME | Change to attributes |
ANTI-CANCER DRUG PROGRAMME | Change to relationships |
ANTI-CANCER DRUG REGIMEN | New Class |
CANCER CARE SPELL | New Class |
CARE SPELL | Change to relationships |
CONSULTANT | Change to relationships |
DRUG DOSAGE AND ADMINISTRATION | Change to relationships |
HEALTH CARE PROVIDER | Change to relationships |
OPERATING THEATRE SESSION | Change to relationships |
Attribute Definitions | |
ANTI-CANCER DRUG CYCLE IDENTIFIER | New Attribute |
ANTI-CANCER DRUG FRACTION IDENTIFIER | New Attribute |
ANTI-CANCER DRUG REGIMEN IDENTIFIER | New Attribute |
DRUG REGIMEN ACRONYM | New Attribute |
DRUG THERAPY TYPE | New Attribute |
Diagrams | |
HP400 CANCER CARE DRUG PROGRAMMES | New NHSDisplayDiagram |
Supporting Information | |
HP400 | New WebPage |
Name: | Barbara Fogarty |
Date: | 28 November 2002 |
Sponsor: | Data Standards Team |
The period of time during which anti-cancer drugs are administered to a PATIENT in an agreed pattern. Cycle is a long-established term used to denote the repeating pattern of many chemotherapy programmes/regimens. A new ANTI-CANCER DRUG CYCLE commences when the original pattern starts again. An
References:
National Cancer Data Set Version 1.2 December 2001
Context | Alias |
---|---|
plural | ANTI-CANCER DRUG CYCLES |
Attributes of this Class are:
K | ANTI-CANCER DRUG CYCLE IDENTIFIER | |
O | END DATE | |
START DATE |
Each ANTI-CANCER DRUG CYCLE
K | must be administered within one and only one ANTI-CANCER DRUG REGIMEN |
may be comprised of one or more ANTI-CANCER DRUG FRACTION |
The actual administration of one or more anti-cancer drugs to a PATIENT. The fraction usually equates to a single contact with a chemotherapy nurse specialist.
References:
National Cancer Data Set Version 1.2 December 2001
Context | Alias |
---|---|
plural | ANTI-CANCER DRUG FRACTIONS |
Attributes of this Class are:
K | ANTI-CANCER DRUG FRACTION IDENTIFIER | |
START DATE |
Each ANTI-CANCER DRUG FRACTION
K | must be administered within one and only one ANTI-CANCER DRUG CYCLE |
may be comprised of one or more DRUG DOSAGE AND ADMINISTRATION |
A course of anti-cancer drug treatment. This can include chemotherapy, immunotherapy, etc.
Two or more ANTI-CANCER DRUG REGIMENS may be given sequentially as part of a planned
References:
National Cancer Data Set Version 1.1_ISB October 2001
Context | Alias |
---|---|
plural | ANTI-CANCER DRUG PROGRAMMES |
Attributes of this Class are:
K | ANTI-CANCER DRUG PROGRAMME IDENTIFIER | |
DRUG THERAPY TYPE | ||
O | END DATE | |
START DATE |
Each ANTI-CANCER DRUG PROGRAMME
K | must be provided in one and only one CANCER CARE SPELL |
must be the responsibility of one and only one CONSULTANT | |
must be managed by one and only one HEALTH CARE PROVIDER | |
may be comprised of one or more ANTI-CANCER DRUG REGIMEN | |
may be part of one and only one SERVICE PROVIDED |
A prescribed systematic form of treatment for a course of drug(s), comprising one or more ANTI-CANCER DRUG CYCLES, provided to a patient suffering from cancer.
References:
National Cancer Data Set Version 1.2 December 2001
Context | Alias |
---|---|
plural | ANTI-CANCER DRUG REGIMENS |
Attributes of this Class are:
K | ANTI-CANCER DRUG REGIMEN IDENTIFIER | |
DRUG REGIMEN ACRONYM | ||
O | END DATE | |
START DATE |
Each ANTI-CANCER DRUG REGIMEN
K | must be within one and only one ANTI-CANCER DRUG PROGRAMME |
may be a regimen containing one or more ANTI-CANCER DRUG CYCLE |
A type of CARE SPELL.
The period of time during which a PATIENT who has been diagnosed as suffering from a single site primary cancer may receive care. The
A recurrence of the original primary cancer at a secondary site is part of the same
If a PATIENT has another primary cancer this will be a new
The
References:
National Cancer Data Set Version 1.2 December 2001
Context | Alias |
---|---|
plural | CANCER CARE SPELLS |
This class has no attributes.
Each CANCER CARE SPELL
may be the context for one or more ANTI-CANCER DRUG PROGRAMME |
Each CARE SPELL
K | must be for the care or assessment of one and only one PERSON |
may be the spell that includes one or more CARE PLAN | |
may be delivered as part of one and only one JOINT INVESTMENT PLAN | |
may be the context for one or more PALLIATIVE CARE EPISODE | |
may be the responsibility of one or more RESPONSIBLE HEALTH CARE PROVIDER | |
may be associated with one or more SERVICE PROVIDED |
Each CONSULTANT
must be contracted as main specialty by a provider for one and only one SPECIALTY | |
may be responsible for one or more ANTI-CANCER DRUG PROGRAMME | |
may be related to one or more CONSULTANT CLINIC | |
may be related to one or more CONSULTANT OUT-PATIENT EPISODE | |
may be related to one or more CONSULTANT REFERRAL REQUEST | |
may be contracted for one or more CONSULTANT SPECIALTY FUNCTION | |
may be related to one or more DOMICILIARY CONSULTATION | |
may be related to one or more ELECTIVE ADMISSION LIST ENTRY | |
may be responsible for one or more FACE TO FACE CONTACT OPTICAL | |
may be related to one or more ISOTOPE PROCEDURE DEPARTMENT | |
may be responsible for one or more NURSING HOME STAY (CONSULTANT CARE) | |
may be related to one or more OPERATING THEATRE SESSION | |
may be related to one OPERATING THEATRE SESSION | |
may be related to one or more PATHOLOGY DEPARTMENT | |
may be related to one PATIENT PROCEDURE | |
may be related to one or more PHYSIOLOGICAL MEASUREMENT DEPARTMENT | |
may be related to one or more RADIOLOGY DEPARTMENT | |
may be related to one or more REFERRAL REQUEST | |
may be related to one or more RIGHT OF ADMISSION | |
may be related to one or more SHARED CARE CONSULTANT | |
may be related to one or more SHARED CARE OUT-PATIENT CONSULTANT | |
may be related to one or more SHARED CLINIC CONSULTANT | |
may be related to one or more THEATRE CASE | |
may be related to one or more WARD INTENDED BED USE |
Each DRUG DOSAGE AND ADMINISTRATION
K | must be related to one and only one DRUG TREATMENT |
may be provided in one and only one ANTI-CANCER DRUG FRACTION | |
may be related to one and only one READ CLASSIFICATION |
Each HEALTH CARE PROVIDER
K | must be a role of one and only one ORGANISATION |
may be the provider of one or more ANTI-CANCER DRUG PROGRAMME | |
may be related to one or more DENTAL STAFF MEMBER | |
may be related to one or more DOMICILIARY SERVICE | |
may be related to one or more ELECTIVE ADMISSION LIST | |
may be acting as one or more HOSPITAL PROVIDER | |
may be originating care provider one or more MENTAL HEALTH CARE SPELL | |
may be the transfer target for one or more MENTAL HEALTH CARE SPELL SUSPENSION | |
may be related to one or more NURSE OR MIDWIFE CONTACT | |
may be related to one or more OPERATING THEATRE | |
may be related to one or more OUT-PATIENT CLINIC | |
may be related to one or more PATHOLOGY DEPARTMENT | |
may be connected with one or more PERSON ROLE IN ORGANISATION | |
may be related to one or more PLANNED SERVICE TO BE PROVIDED | |
may be related to one or more PROFESSIONAL STAFF GROUP SERVICE | |
may be the provider in one or more PROVIDER IN SERVICE AGREEMENT | |
may be the provider in one or more PROVIDER OF OUT OF AREA TREATMENT | |
may be related to one or more RADIOLOGY DEPARTMENT | |
may be related to one or more RADIOTHERAPY DEPARTMENT | |
may be responsible for one or more RESPONSIBLE HEALTH CARE PROVIDER | |
may be related to one or more RIGHT OF ADMISSION | |
may be delivering patient treatment or services by one or more SERVICE PROVIDED | |
may be related to one or more WARD |
Each OPERATING THEATRE SESSION
K | must be related to one and only one OPERATING THEATRE |
may be the actual responsibility of one and only one CONSULTANT | |
may be planned for one or more CONSULTANT | |
may be related to one and only one SPECIALTY FUNCTION | |
may be related to one or more THEATRE CASE | |
may be cancelled due to one and only one THEATRE SESSION CANCELLATION REASON |
A unique identifier for an ANTI-CANCER DRUG CYCLE within an ANTI-CANCER DRUG REGIMEN.
References:
National Cancer Data Set Version 1.1_ISB October 2001
A unique identifier for an ANTI-CANCER DRUG FRACTION within an ANTI-CANCER DRUG CYCLE.
References:
National Cancer Data Set Version 1.1_ISB October 2001
A unique identifier for an ANTI-CANCER DRUG REGIMEN within an ANTI-CANCER DRUG PROGRAMME.
References:
National Cancer Data Set Version 1.1_ISB October 2001
The acronym derived from the drugs used in the ANTI-CANCER DRUG REGIMEN used to identify the drugs used in the regimen. Examples include 'CMF' for a regimen comprising Cyclophosphamide, Methotrexate and 5-Fluorouracil, 'AC' for a regimen comprising Dorubicin and Cyclophosphamide, etc..
References:
National Cancer Data Set Version 1.2 December 2001
A classification of the type of drug therapy in the ANTI-CANCER DRUG PROGRAMME.
National Codes:
C | Chemotherapy |
H | Hormone / endocrine therapy |
I | Immunotherapy |
O | Other |
References:
National Cancer Data Set Version 1.2 December 2001
HP400 CANCER CARE DRUG PROGRAMMES
Model View Diagram - Overview |
This diagram shows the class types relevant to chemotherapy interventions in the treatment of cancer.
An ANTI-CANCER DRUG PROGRAMME is planned under the responsibility of a CONSULTANT during a CANCER CARE SPELL and may be comprised of a number of ANTI-CANCER DRUG REGIMENS which run sequentially.
An
The actual administration to a PERSON of one or more anti-cancer DRUG DOSAGES AND ADMINISTRATIONS is an ANTI-CANCER DRUG FRACTION.
An